Zymo Research Corporation, a leader in innovative life science solutions, acknowledges the patent infringement lawsuit filed by Qiagen GmbH on August 20, 2024, at the US District Court for the Central District of California regarding its MAGicBead cfDNA isolation technology. Zymo Research respects intellectual property rights and is confident that this technology represents a significant advancement in nucleic acid purification.
“Our MAGic cfDNA purification system is a groundbreaking innovation,” said Dr. Larry Jia, Founder and CEO of Zymo Research. “While this legal challenge places a significant burden on our resources as a small company, our commitment to the scientific community is stronger than ever.”
For over 30 years, Zymo Research, a company of “Scientists for Scientists,” has delivered innovative solutions to meet the evolving needs of researchers. Despite being a modestly sized company with around 250 employees, Zymo Research offers cutting-edge solutions from genetic, epigenetic, and microbiomic research tools to eco-friendly sample transport solutions. This is owed to prioritizing a culture of innovation, quality, and customer service.
“Our success is rooted in the trust of our customers and researchers worldwide,” said Dr. Marc Van Eden, VP of Corporate Development. “We are committed to giving back to the community with the best, most innovative products.”
Despite this legal challenge, Zymo Research remains focused on its mission of advancing life science with reliable solutions trusted by thousands of researchers globally and serves as a reminder of their unwavering commitment to science and the betterment of humanity.
